Added to YB: 2025-07-16
Pitch date: 2025-06-17
CRVS [bullish]
Corvus Pharmaceuticals, Inc.
+342.68%
current return
Author Info
No bio for this author
Company Info
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Market Cap
$1.6B
Pitch Price
$3.96
Price Target
140.00 (+699%)
Dividend
N/A
EV/EBITDA
-36.11
P/E
-33.40
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Corvus Pharmaceuticals, Inc. - $CRVS
CRVS: Biopharmaceutical company with oral ITK inhibitor Soquelitinib targeting immune disorders. Key indications: T-cell lymphoma (FDA Fast Track), atopic dermatitis ($30B+ market by 2034), and rare ALPS. Potential acquisition target at $300M cap vs $10-75B projected exit. Led by Dr. Miller who developed Rituxan and Imbruvica ($6B+ annual sales each).